Get to know our clinical trials
Prolongation trial to evaluate the safety and efficacy of lebrikizumab in participants aged 6 months to less than 18 years with moderate to severe atopic dermatitis.
THE MAIN REASON FOR YOUR PARTICIPATION IN THE STUDY IS NOT TO PROVIDE TREATMENT FOR YOUR DISEASE, BUT TO HELP FIND AN ANSWER TO THE FOLLOWING SCIENTIFIC QUESTION: THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN TAKEN OVER A PROLONGED PERIOD OF TIME.
Status
In recruitment
headquarters
Pamplona
Technical Summary
- LONG-TERM, PHASE 3, MULTICENTER, PROLONGATION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS AGED 6 MONTHS TO LESS THAN 18 YEARS WITH MODERATE TO SEVERE ATOPIC DERMATITIS. IMMUNOTHERAPY
- Code EudraCT: 2022-501478-21-00
- Protocol number: J2T-MC-KGBJ
- Promoter: Lilly
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.